Last SFr.85.00 CHF
Change Today +0.20 / 0.24%
Volume 3.2K
YPSN On Other Exchanges
Symbol
Exchange
YPSN is not on other exchanges.
As of 11:43 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

ypsomed holding ag-reg (YPSN) Snapshot

Open
SFr.84.65
Previous Close
SFr.84.80
Day High
SFr.85.80
Day Low
SFr.84.45
52 Week High
04/30/14 - SFr.93.67
52 Week Low
07/24/13 - SFr.54.81
Market Cap
1.1B
Average Volume 10 Days
5.5K
EPS TTM
SFr.1.08
Shares Outstanding
12.6M
EX-Date
07/7/14
P/E TM
78.7x
Dividend
SFr.0.30
Dividend Yield
0.35%
Current Stock Chart for YPSOMED HOLDING AG-REG (YPSN)

Related News

No related news articles were found.

ypsomed holding ag-reg (YPSN) Related Businessweek News

No Related Businessweek News Found

ypsomed holding ag-reg (YPSN) Details

Ypsomed Holding AG develops, manufactures, and sells injection pens for pharmaceutical and biotech companies worldwide. The company operates in two segments, Delivery Devices and Diabetes Direct Business. The Delivery Devices segment products include pen systems, pen needles, infusion sets, and other injection moldings products. The Diabetes Direct Business sells and trades devices for the self-monitoring of blood glucose levels, as well as infusion pumps, accessories, and other day-to-day items for diabetics. It offers insulin pumps, injection systems, and pen needles for the treatment of diabetes, growth disorders, infertility, and other therapeutic areas; and pen needles under the mylife Diabetescare brand for the treatment of diabetes. Ypsomed Holding AG markets its products through biotech and pharmaceutical partners, as well as through its own distribution network and independent distributors. The company was founded in 1984 and is headquartered in Burgdorf, Switzerland.

958 Employees
Last Reported Date: 05/27/14
Founded in 1984

ypsomed holding ag-reg (YPSN) Top Compensated Officers

Senior Vice President of Legal & Intellectual...
Total Annual Compensation: SFr.387.0K
Compensation as of Fiscal Year 2014.

ypsomed holding ag-reg (YPSN) Key Developments

Ypsomed Holding AG Announces Earnings Results for the Year Ended March 31, 2014

Ypsomed Holding AG announced earnings results for the year ended March 31, 2014. For the period, the company reported operating profit of CHF 15,645,000 compared to CHF 4,846,000 a year ago. Earnings per share were CHF 1.08 compared to CHF 0.13 a year ago. Research and development expenditures, total were CHF 23,461,000 compared to CHF 23,650,000 a year ago. Investment in fixed assets was CHF 18,530,000 compared to CHF 15,945,000 a year ago.

Ypsomed Holding AG Provides Earnings Guidance for the Year Ending March 31, 2015

Ypsomed Holding AG provided earnings guidance for the year ending March 31, 2015. For the year, the company expects further increase in both revenue and operating profit after the strong performance in the previous year. Revenue in the year through March 31, 2015 is expected to grow by 10% while earnings before interest and tax (EBIT) would jump by about 40% on the year. The growth outlook is based on three contracts for injection systems signed with GlaxoSmithKline, Palatin Technologies and Pharmstandard.

Ypsomed Announces Earnings Results for the Year Ended March 31, 2014

Ypsomed announced earnings results for the year ended March 31, 2014. The company achieved a turnaround in fiscal 2014, with net profit soaring by CHF 12 million (USD 13.7 million/EUR 9.84 million) to CHF 14 million. The firm more than tripled earnings before interest and tax (EBIT) to CHF 16 million from CHF 5 million. Revenue grew 13% to CHF 276 million, with all segments contributing to the growth.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
YPSN:SW SFr.85.00 CHF +0.20

YPSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.18 USD -0.03
Becton Dickinson and Co $118.61 USD +0.37
Terumo Corp ¥2,312 JPY -1.00
Unilife Corp $2.67 USD -0.01
West Pharmaceutical Services Inc $40.76 USD +0.16
View Industry Companies
 

Industry Analysis

YPSN

Industry Average

Valuation YPSN Industry Range
Price/Earnings 77.4x
Price/Sales 3.8x
Price/Book 4.6x
Price/Cash Flow 77.7x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact YPSOMED HOLDING AG-REG, please visit www.ypsomed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.